Fujifilm made an initial $10 million investment to establish a full-scale, fully-integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at Fujifilm Diosynth Biotechnologies in Billingham, U.K., location.

Fujifilm officials say their advanced upstream perfusion process utilizes a proprietary process control system with automatic feedback control for cell density and nutrient addition to maintain steady-state conditions. The company also has developed an in-house, defined medium suitable for high-density perfusion culture and has adapted its Apollo™ X cell line for perfusion processing, they added.

According to Fujifilm, a patented multi-functional system for downstream purification will be available and able to deliver all required unit operations including chromatography, ultra and dia-filtration, (UFDF), single pass tangential flow (SP-TFF), viral inactivation and filtration, and point of use in-line preparation of buffers within a common single-use flow path. This technology reportedly can be deployed in both batch and continuous processing environments.

The new facility will include a 500 L single-use perfusion bioreactor and seven patented downstream processing units that are expected to yield >15kg of antibody from a single four-week batch at 500 L scale, noted the company. The system will be available for process development services in Fall 2019.

Previous articleVertex Grows Gene Editing Presence, Acquiring Exonics and Expanding CRISPR Therapeutics Collaboration
Next articleJacobs Wins Contract to Provide Construction Services for WuXi